🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 19 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 27/03/2003 | 11,26 | 11,59 | 11,00 | 11,50 | +2,31% | 5,24% | 473.400 |
| 26/03/2003 | 11,20 | 11,39 | 11,17 | 11,24 | +0,54% | 1,96% | 376.600 |
| 25/03/2003 | 11,01 | 11,24 | 10,99 | 11,18 | +2,10% | 2,27% | 650.000 |
| 24/03/2003 | 11,36 | 11,55 | 10,92 | 10,95 | -3,95% | 5,55% | 814.400 |
| 21/03/2003 | 11,54 | 11,76 | 11,04 | 11,40 | +3,07% | 6,24% | 1.193.900 |
| 20/03/2003 | 11,15 | 11,23 | 10,50 | 11,06 | +0,18% | 6,55% | 555.400 |
| 19/03/2003 | 11,41 | 11,79 | 10,58 | 11,04 | -1,52% | 10,60% | 636.200 |
| 18/03/2003 | 10,92 | 11,29 | 10,60 | 11,21 | +3,41% | 6,32% | 897.100 |
| 17/03/2003 | 10,14 | 10,97 | 10,00 | 10,84 | +7,65% | 9,57% | 715.700 |
| 14/03/2003 | 10,34 | 10,42 | 10,01 | 10,07 | -2,33% | 3,97% | 495.900 |
| 13/03/2003 | 9,98 | 10,46 | 9,74 | 10,31 | +6,07% | 7,21% | 624.900 |
| 12/03/2003 | 10,11 | 10,39 | 9,68 | 9,72 | -3,67% | 7,02% | 927.500 |
| 11/03/2003 | 10,38 | 10,48 | 10,04 | 10,09 | -2,79% | 4,24% | 401.900 |
| 10/03/2003 | 10,20 | 10,50 | 10,14 | 10,38 | -0,19% | 3,53% | 817.000 |
| 07/03/2003 | 9,63 | 10,65 | 9,59 | 10,40 | +1,46% | 11,01% | 1.397.100 |
| 06/03/2003 | 10,10 | 10,37 | 9,97 | 10,25 | +1,49% | 3,96% | 671.300 |
| 05/03/2003 | 10,51 | 10,67 | 10,05 | 10,10 | -5,34% | 5,90% | 790.500 |
| 04/03/2003 | 10,89 | 11,00 | 10,61 | 10,67 | -2,91% | 3,58% | 454.300 |
| 03/03/2003 | 10,91 | 11,38 | 10,90 | 10,99 | -0,54% | 4,40% | 532.000 |
| 28/02/2003 | 11,18 | 11,21 | 10,85 | 11,05 | +0,27% | 3,22% | 593.300 |
| 27/02/2003 | 11,39 | 11,48 | 10,95 | 11,02 | -2,65% | 4,65% | 654.600 |
| 26/02/2003 | 11,22 | 11,67 | 11,17 | 11,32 | +0,09% | 4,46% | 880.800 |
| 25/02/2003 | 11,60 | 11,79 | 11,10 | 11,31 | -3,33% | 5,95% | 1.040.500 |
| 24/02/2003 | 12,53 | 12,53 | 11,61 | 11,70 | -5,65% | 7,34% | 471.600 |
| 21/02/2003 | 11,61 | 12,43 | 11,55 | 12,40 | +1,39% | 7,58% | 777.900 |
| 20/02/2003 | 12,59 | 12,60 | 11,93 | 12,23 | -1,85% | 5,32% | 885.700 |
| 19/02/2003 | 13,02 | 13,07 | 12,28 | 12,46 | -2,50% | 6,07% | 549.600 |
| 18/02/2003 | 12,14 | 12,80 | 11,95 | 12,78 | +1,51% | 7,00% | 900.900 |
| 14/02/2003 | 13,66 | 13,69 | 12,40 | 12,59 | -4,48% | 9,44% | 1.144.800 |
| 13/02/2003 | 13,74 | 13,74 | 13,12 | 13,18 | -4,01% | 4,51% | 552.800 |